The Effects AZD8529 on Cognition and Negative Symptoms in Schizophrenics

Completed · Phase 1 · Has a placebo group

Conditions studied: Schizophrenia

In brief

The purpose of this study is to assess if AZD8529 improves performance on neurobehavioral probes of attention, working memory and affective reactivity in patients with schizophrenia.

Key facts

Study ID

NCT00986531

Run by

AstraZeneca

People needed

59

Starts

2009-11-01

Expected to finish

2011-10-01

Last updated by the study team

2011-11-01

Who can join

Age: 18 and older, up to 45. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• DSM-IV diagnosis of schizophrenia or schizoaffective disorder

You may not qualify if…

• ECT in the last 6 months
• Substance abuse or dependence
• History of claustrophobia

Where it is running

• Research Site — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.